Stansberry Asset Management LLC Has $7.43 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Stansberry Asset Management LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 62,423 shares of the company’s stock after buying an additional 3,142 shares during the period. Stansberry Asset Management LLC’s holdings in Novo Nordisk A/S were worth $7,433,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Envestnet Asset Management Inc. grew its stake in shares of Novo Nordisk A/S by 1.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock worth $607,242,000 after acquiring an additional 58,935 shares in the last quarter. Raymond James & Associates grew its stake in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares in the last quarter. Natixis Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. Finally, DSM Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.2 %

NVO stock opened at $108.96 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a fifty day moving average price of $111.82 and a two-hundred day moving average price of $127.46. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The stock has a market cap of $488.96 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 1.41 and a beta of 0.40.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NVO shares. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $150.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.